Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term therapeutic use. Found 398 abstracts

no pagination
Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F, National Comprehensive Cancer N. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2008 Apr;6(4):356-421.
Astsaturov I, Cohen RB, Harari P. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets. 2007 Nov;7(7):650-65.
Eade TN, Al-Saleem T, Horwitz EM, Buyyounouski MK, Chen DY, Pollack A. Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. Cancer. 2007 May 15;109(10):2011-5.
Forastiere AA, Burtness BA. Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions. J Clin Oncol. 2007 Jun;25(16):2152-5.
Haas NB, Uzzo RG. Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer. Current treatment options in oncology. 2007 Jun;8(3):211-26.
Jordan VC. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids. 2007 Nov;72(13):829-42.
Jordan VC. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point. Cancer Epidemiology, Biomarkers and Prevention. 2007 Nov;16(11):2207-9.
Jordan VC, Gelber RD. Problems with the progesterone receptor in practice?. J Clin Oncol. 2007 May 20;25(15):1957-9.
Langer CJ. Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer. J Clin Oncol. 2007 Mar;25(7):751-3.
Langer CJ, Fastenau JM, Forlenza JB, Tak Piech C, Bolge SC, Gano Allen J, Zilberberg MD. Effectiveness versus convenience: patient preferences for an erythropoietic agent to treat cancer-related anemia. Curr Med Res Opin. 2007 Jan;23(1):85-92.
Litwin S, Wong YN, Hudes G. Early stopping designs based on progression-free survival at an early time point in the initial cohort. Statistics in medicine. 2007 Oct 30;26(24):4400-15.
Swaby RF, Sharma CG, Jordan VC. SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord. 2007 Sep;8(3):229-39.
von Gegerfelt AS, Rosati M, Alicea C, Valentin A, Roth P, Bear J, Franchini G, Albert PS, Bischofberger N, Boyer JD, Weiner DB, Markham P, Israel ZR, Eldridge JH, Pavlakis GN, Felber BK. Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. Journal of Virology. 2007 Feb;81(4):1972-9.   PMCID: 1797580
Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006 Sep 10;24(26):4324-32.
Gorin SS, Wang C, Raich P, Bowen DJ, Hay J. Decision making in cancer primary prevention and chemoprevention. Ann Behav Med. 2006 Dec;32(3):179-87.
Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. British journal of pharmacology. 2006 Jan;147 Suppl 1:S269-76.
Konski A, Watkins-Bruner D, Feigenberg S, Hanlon A, Kulkarni S, Beck JR, Horwitz EM, Pollack A. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Aug;66(2):408-15.
Ma CM, Maughan RL. Within the next decade conventional cyclotrons for proton radiotherapy will become obsolete and replaced by far less expensive machines using compact laser systems for the acceleration of the protons. Med Phys. 2006 Mar;33(3):571-3.
Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol. 2006 Jul;24(19):3107-12.
Wetherbee SL. New weapons to snuff out kidney cancer. Nursing. 2006 Dec;36(12 Pt.1):58-63; quiz 64.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term therapeutic use

therapeutic use drug therapy Female Breast Neoplasms Tamoxifen metabolism Antineoplastic Agents prevention & control Male Aged therapy methods pathology Postmenopause Epidermal Growth Factor Receptor Monoclonal Antibodies Disease-Free Survival adverse effects immunology antagonists & inhibitors administration & dosage Hormonal Antineoplastic Agents Immunotherapy Middle Aged Protein Kinase Inhibitors Treatment Outcome Androgen Antagonists Raloxifene Antineoplastic Combined Chemotherapy Protocols Prostatic Neoplasms radiotherapy mortality Neoplasms Squamous Cell Carcinoma Adult Head and Neck Neoplasms Anticarcinogenic Agents Non-Hodgkin Lymphoma genetics economics Kidney Neoplasms Neoplasm Staging Quinazolines 80 and over Aged Renal Cell Carcinoma Clinical Trials as Topic Selective Estrogen Receptor Modulators Protein-Tyrosine Kinases Lung Neoplasms Simian Acquired Immunodeficiency Syndrome classification Estrogen Antagonists Angiogenesis Inhibitors nursing Dimerization Age Factors Molecular Mimicry blood Rats Questionnaires Monte Carlo Method Local Neoplasm Recurrence Vaccination Non-Small-Cell Lung Carcinoma Erythropoietin Intramuscular Injections use Immunohistochemistry Hormone Replacement Therapy veterinary Cyclotrons DNA Vaccines Pyrroles Viral Load Progesterone Receptors Premenopause Intensity-Modulated Radiotherapy Enzyme-Linked Immunosorbent Assay Decision Support Techniques etiology Immunoglobulin Idiotypes Primary Prevention Lasers Preclinical Drug Evaluation therapeutic adverse Radiotherapy Dosage Neoplastic Gene Expression Regulation Quality-Adjusted Life Years Radiotherapy history Markov Chains statistics & numerical data SAIDS Vaccines 21st Century History effects Papillomavirus Infections Prognosis Predictive Value of Tests Protons United States instrumentation Polymerase Chain Reaction Estrogen Receptors Viral Antigens Postoperative Care diagnosis Adjuvant Chemotherapy Nephrectomy Quality of Life enzymology Risk Factors Pathologic Neovascularization 20th Century History Cellular Immunity Conformal Radiotherapy Anemia standards Forecasting Biological Tumor Markers Prostate-Specific Antigen erbB-2 Receptor trends Phase II Clinical Trials as Topic Portraits as Topic Statistical Models Pyridines Ductal Carcinoma Viral Vaccines Health Care Costs Antibody-Dependent Cell Cytotoxicity Gene Dosage Decision Making Indoles Patient Satisfaction Time Factors Drug Administration Schedule Computer Simulation erbB-2 Genes analysis Simian immunodeficiency virus Combined Modality Therapy complications Chi-Square Distribution psychology Chronic Disease Antibody Formation blood supply Papillomavirus Vaccines Macaca mulatta
Last updated on Wednesday, February 05, 2020